BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36037469)

  • 1. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19.
    ; Rogers AJ; Wentworth D; Phillips A; Shaw-Saliba K; Dewar RL; Aggarwal NR; Babiker AG; Chang W; Dharan NJ; Davey VJ; Higgs ES; Gerry N; Ginde AA; Hayanga JWA; Highbarger H; Highbarger JL; Jain MK; Kan V; Kim K; Lallemand P; Leshnower BG; Lutaakome JK; Matthews G; Mourad A; Mylonakis E; Natarajan V; Padilla ML; Pandit LM; Paredes R; Pett S; Ramachandruni S; Rehman MT; Sherman BT; Files DC; Brown SM; Matthay MA; Thompson BT; Neaton JD; Lane HC; Lundgren JD
    Ann Intern Med; 2022 Oct; 175(10):1401-1410. PubMed ID: 36037469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
    ; Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Goodman AL; Chang W; Dewar RL; Gerry NP; Higgs ES; Highbarger H; Murray DD; Murray TA; Natarajan V; Paredes R; Parmar MKB; Phillips AN; Reilly C; Rupert AW; Sharma S; Shaw-Saliba K; Sherman BT; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Davey VJ; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD
    Ann Intern Med; 2022 Feb; 175(2):234-243. PubMed ID: 34928698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19.
    Wick KD; Leligdowicz A; Willmore A; Carrillo SA; Ghale R; Jauregui A; Chak SS; Nguyen V; Lee D; Jones C; Dewar R; Lane HC; Kangelaris KN; Hendrickson CM; Liu KD; Sinha P; Erle DJ; Langelier CR; Krummell MF; Woodruff PG; Calfee CS; Matthay MA;
    Crit Care; 2022 Sep; 26(1):278. PubMed ID: 36104754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.
    Aggarwal NR; Nordwall J; Braun DL; Chung L; Coslet J; Der T; Eriobu N; Ginde AA; Hayanga AJ; Highbarger H; Holodniy M; Horcajada JP; Jain MK; Kim K; Laverdure S; Lundgren J; Natarajan V; Nguyen HH; Pett SL; Phillips A; Poulakou G; Price DA; Robinson P; Rogers AJ; Sandkovsky U; Shaw-Saliba K; Sturek JM; Trautner BW; Waters M; Reilly C;
    Clin Infect Dis; 2024 Jun; 78(6):1490-1503. PubMed ID: 38376212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.
    Jensen TO; Murray TA; Grandits GA; Jain MK; Grund B; Shaw-Saliba K; Matthay MA; Abassi M; Ardelt M; Baker JV; Chen P; Dewar RL; Goodman AL; Hatlen TJ; Highbarger HC; Holodniy M; Lallemand P; Laverdure S; Leshnower BG; Looney D; Moschopoulos CD; Mugerwa H; Murray DD; Mylonakis E; Nagy-Agren S; Rehman MT; Rupert A; Stevens R; Turville S; Weintrob A; Wick K; Lundgren J; Ko ER;
    Lancet Microbe; 2024 Jun; 5(6):e559-e569. PubMed ID: 38815595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative.
    Bennett TD; Moffitt RA; Hajagos JG; Amor B; Anand A; Bissell MM; Bradwell KR; Bremer C; Byrd JB; Denham A; DeWitt PE; Gabriel D; Garibaldi BT; Girvin AT; Guinney J; Hill EL; Hong SS; Jimenez H; Kavuluru R; Kostka K; Lehmann HP; Levitt E; Mallipattu SK; Manna A; McMurry JA; Morris M; Muschelli J; Neumann AJ; Palchuk MB; Pfaff ER; Qian Z; Qureshi N; Russell S; Spratt H; Walden A; Williams AE; Wooldridge JT; Yoo YJ; Zhang XT; Zhu RL; Austin CP; Saltz JH; Gersing KR; Haendel MA; Chute CG;
    JAMA Netw Open; 2021 Jul; 4(7):e2116901. PubMed ID: 34255046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar.
    Butt AA; Dargham SR; Chemaitelly H; Al Khal A; Tang P; Hasan MR; Coyle PV; Thomas AG; Borham AM; Concepcion EG; Kaleeckal AH; Latif AN; Bertollini R; Abou-Samra AB; Abu-Raddad LJ
    JAMA Intern Med; 2022 Feb; 182(2):197-205. PubMed ID: 34935861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19.
    Wang H; Hogan CA; Verghese M; Solis D; Sibai M; Huang C; Röltgen K; Stevens BA; Yamamoto F; Sahoo MK; Zehnder J; Boyd SD; Pinsky BA
    Clin Chem; 2021 Dec; 68(1):204-213. PubMed ID: 34605900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.